Zacks: Brokerages Expect Nightstar Therapeutics (NITE) to Announce -$0.39 Earnings Per Share

Equities research analysts forecast that Nightstar Therapeutics (NASDAQ:NITE) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Nightstar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.48). The company is expected to report its next quarterly earnings results on Tuesday, July 3rd.

According to Zacks, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.83) per share for the current fiscal year, with EPS estimates ranging from ($2.37) to ($1.16). For the next financial year, analysts expect that the business will report earnings of ($1.65) per share, with EPS estimates ranging from ($1.98) to ($1.22). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.

A number of research analysts have weighed in on NITE shares. Zacks Investment Research downgraded Nightstar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 7th. Mizuho started coverage on Nightstar Therapeutics in a research report on Tuesday, February 27th. They issued a “buy” rating and a $20.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Nightstar Therapeutics in a research report on Thursday, April 5th. Finally, ValuEngine raised Nightstar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Nightstar Therapeutics currently has an average rating of “Buy” and an average target price of $28.50.

A hedge fund recently bought a new stake in Nightstar Therapeutics stock. Millennium Management LLC purchased a new position in Nightstar Therapeutics (NASDAQ:NITE) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 35,308 shares of the company’s stock, valued at approximately $507,000. Millennium Management LLC owned approximately 0.13% of Nightstar Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 29.19% of the company’s stock.

Shares of Nightstar Therapeutics traded down $0.20, reaching $13.80, during midday trading on Friday, MarketBeat.com reports. 19,256 shares of the stock were exchanged, compared to its average volume of 10,333. Nightstar Therapeutics has a 1 year low of $10.01 and a 1 year high of $24.93. The company has a market capitalization of $387.78 million and a price-to-earnings ratio of -8.47.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply